

Formulating Pharma-, Nutra-, and Cosmeceutical Products from Herbal Substances

Dosage Forms and Delivery Systems

Edited by

Anupama Singh

Hitesh Kulhari

Vikas Anand Saharan



WILEY

Formulating Pharma-, Nutra-, and Cosmeceutical Products from Herbal Substances

Formulating Pharma-, Nutra-, and Cosmeceutical Products from Herbal Substances

Dosage Forms and Delivery Systems

Edited by

Anupama Singh

School of Pharmaceutical Sciences and Technology
Sardar Bhagwan Singh University
Dehradun, Uttarakhand
India

Hitesh Kulhari

School of Nano Sciences Central University of Gujarat
Gandhinagar, Gujarat
India

Vikas Anand Saharan

Department of Pharmaceutical Technology (Formulations)
National Institute of Pharmaceutical Education and Research-Guwahati (NIPER-G)
Changsari, Assam
India

WILEY

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

The manufacturer's authorized representative according to the EU General Product Safety Regulation is WILEY-VCH GmbH, Boschstr. 12, 69469 Weinheim, Germany, e-mail: Product_Safety@wiley.com.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data applied for:

Hardback ISBN 9781119769477

Cover Design: Wiley

Cover Images: © Iryna Veklich/Getty Images, © Eddie Gerald/Getty Images, © wera Rodsawang/Getty Images, © RUNSTUDIO/Getty Images

Set in 9.5/12.5pt STIXTwoText by Straive, Chennai, India

*Dr. Anupama Singh and Dr. Vikas Anand Saharan would like to dedicate this book to their sons **Inesh and Krit** whose smiles and tantrums have added color and vibrancy to their writing experience.*

Contents

List of Contributors	<i>xxxi</i>
Foreword by Prof. J.M.S. Rana	<i>xxxix</i>
Foreword by Prof. Anil Bhandari	<i>xli</i>
About the Editors	<i>xlili</i>
Preface	<i>xlvi</i>

Section I Introduction and Basic Principles 1

1	From Traditional to Modern Medicine: The Role of Herbs and Phytoconstituents in Pharmaceuticals, Nutraceuticals, and Cosmetics	3
	<i>Pooja Shah, Surojit Banerjee, Anupama Singh, Hitesh Kulhari, and Vikas Anand Saharan</i>	
	Objectives	3
1.1	Introduction	3
1.1.1	Historical Overview	4
1.2	Traditional Uses of Herbs in Pharmaceuticals, Nutraceuticals, and Cosmeceuticals	5
1.2.1	Ayurvedic System of Medicine	6
1.2.1.1	Global Reliance on Herbal Medicine	6
1.2.1.2	Challenges and Opportunities	6
1.2.1.3	Research Methodology	8
1.2.1.4	Quality and Standardization	9
1.2.1.5	Government and Policy Support	9
1.2.1.6	Literature and Evidence-Based Research	9
1.2.1.7	Clinical Trials and Validation	10
1.2.1.8	Integration with Western Medicine	11
1.2.1.9	Personalized Medicine	12
1.2.2	Unani System of Medicine	12
1.2.2.1	Global Scenario	13
1.2.2.2	Strength of the Unani System of Medicine	13
1.2.2.3	Indian Government Efforts to Globalize the Unani System of Medicine	13
1.2.2.4	Government and Policy Support	14
1.2.3	Siddha System of Medicine	14
1.2.3.1	Global Scenario	14
1.2.3.2	Indian Government Initiatives	14
1.2.3.3	Comprehensive Health Management	15
1.2.3.4	Health Promotion Guidelines	15
1.2.4	Homeopathy System of Medicine	15
1.2.4.1	Global Scenario	15
1.2.4.2	Homeopathy in India's Healthcare System	15
1.2.4.3	Holistic Therapeutic Approaches in Homeopathy	15

1.2.4.4	Scope and Advantages of Homeopathy	16
1.2.4.5	Influence of Homeopathy on Public Health and Scientific Perception	16
1.2.5	Traditional Chinese Medicine	16
1.2.5.1	Key Concepts in Traditional Chinese Medicine and Their Interrelationships	16
1.2.5.2	Global Scenario	17
1.2.5.3	Challenges and Opportunities	17
1.2.5.4	Quality and Standardization	17
1.2.5.5	Government and Policy Support	17
1.2.5.6	Literature and Evidence-Based Research	17
1.2.5.7	Integration with Western Medicine	17
1.2.5.8	Personalized Medicine	17
1.3	Herbs as a Source of Modern Medicine	17
1.4	Herbs as a Source of Nutraceuticals/Dietary Supplements	18
1.5	Herbs as a Source of Cosmeceuticals	18
1.6	Advantages of Herbal Formulations	24
1.6.1	Natural Approach	24
1.6.2	Traditional and Time-Tested Use	24
1.6.2.1	Turmeric (<i>Curcuma longa</i>)	24
1.6.2.2	Chamomile (<i>Matricaria chamomilla</i>)	24
1.6.2.3	Ginseng (<i>Panax ginseng</i>)	24
1.6.2.4	Neem (<i>Azadirachta indica</i>)	24
1.6.2.5	Calendula (<i>Calendula officinalis</i>)	30
1.6.3	Holistic Approach	30
1.6.3.1	Ashwagandha (<i>Withania somnifera</i>)	30
1.6.3.2	Ginkgo (<i>Ginkgo biloba</i>)	30
1.6.3.3	Echinacea (<i>Echinacea purpurea</i>)	30
1.6.3.4	Lavender (<i>Lavandula angustifolia</i>)	30
1.6.3.5	Ginseng (<i>Panax ginseng</i>)	30
1.6.3.6	Turmeric (<i>Curcuma longa</i>)	30
1.6.3.7	Chamomile (<i>Matricaria chamomilla</i>)	30
1.6.4	Fewer Side Effects	30
1.6.5	Customization	31
1.6.6	Accessibility	32
1.6.7	Cultural Significance	32
1.6.8	Pharmacological Activity Enhancement	33
1.7	Challenges of Herbal Formulations	33
1.7.1	Variability in Plant Material	33
1.7.2	Contamination	34
1.7.2.1	Heavy Metal Contamination	34
1.7.2.2	Pesticide Residues	34
1.7.2.3	Microbial Contamination	34
1.7.2.4	Environmental Pollutants	34
1.7.3	Adulteration	34
1.7.3.1	Addition of Synthetic Pharmaceuticals	35
1.7.3.2	Mixing with Cheaper Substitutes	35
1.7.3.3	Contamination with Toxic Substances	35
1.7.3.4	Use of Non-Standardized Plant Parts	35
1.7.3.5	Dilution with Inert Substances	35
1.7.4	Standardization	35
1.7.4.1	Variability in Plant Composition	35
1.7.4.2	Harvesting and Processing Conditions	35
1.7.4.3	Inconsistency in Raw Material Quality	35

1.7.4.4	Complexity of Extracts	36
1.7.4.5	Analytical Challenges	36
1.7.5	Complexity of Herbal Ingredients	36
1.7.5.1	Synergistic Effects	36
1.7.5.2	Variability in Compound Concentrations	36
1.7.5.3	Multiple Active Ingredients	36
1.7.5.4	Complex Chemical Profiles	36
1.7.5.5	Plant Part Variability	36
1.7.6	Limited Clinical Research	37
1.7.6.1	Insufficient Evidence for Efficacy	37
1.7.6.2	Variability in Study Design and Quality	37
1.7.6.3	Lack of Standardized Dosing	37
1.7.6.4	Limited Long-Term Safety Data	37
1.7.6.5	Challenges in Conducting Placebo-Controlled Trials	37
1.7.7	Limited Scientific Evidence	38
1.7.7.1	<i>Garcinia cambogia</i> (<i>Garcinia gummi-gutta</i>)	38
1.7.7.2	<i>Moringa</i> (<i>Moringa oleifera</i>)	38
1.7.7.3	<i>Ashwagandha</i> (<i>Withania somnifera</i>)	38
1.7.7.4	<i>Elderberry</i> (<i>Sambucus nigra</i>)	38
1.7.8	Bioavailability and Absorption	38
1.7.8.1	<i>Resveratrol</i> (<i>Polygonum cuspidatum</i>)	39
1.7.8.2	<i>Quercetin</i>	39
1.7.8.3	<i>Cannabidiol</i> (CBD, <i>Cannabis sativa</i>)	39
1.7.8.4	<i>Berberine</i> (<i>Berberis species</i>)	39
1.7.9	Safety and Toxicity Concerns	39
1.7.9.1	Adulteration and Contamination	39
1.7.9.2	Misidentification of Plants	40
1.7.9.3	Interactions with Pharmaceuticals	40
1.7.9.4	Variable Potency and Dosage Issues	40
1.7.9.5	Lack of Standardization and Regulation	40
1.7.9.6	Toxic Constituents in Plants	40
1.7.9.7	Chronic Use and Long-Term Effects	40
1.7.9.8	Strategies to Mitigate Safety and Toxicity Concerns	40
1.7.10	Legal Issues	40
1.7.10.1	Lack of Standardized Rules across Geographic Regions	40
1.7.10.2	Insufficient Clinical Evidence Requirements	41
1.7.10.3	Challenges in Quality Control	41
1.7.10.4	Lack of Clear Labeling Requirements	41
1.7.10.5	Traditional Use versus Modern Regulatory Standards	41
1.7.10.6	Global Supply Chain and Traceability Issues	41
1.7.11	Herb–Drug Interactions	41
1.7.12	Cultural and Knowledge Barriers	42
1.7.13	Consumer Awareness and Education	43
1.7.13.1	Misrepresentation and False Prescriptions	44
1.7.13.2	Lack of Standardized Information	44
1.7.13.3	Unawareness of Potential Interactions and Side Effects	44
1.7.13.4	Information Inaccessibility	44
1.7.14	Sustainability and Conservation	44
1.7.14.1	Overharvesting of Popular Medicinal Plants	44
1.7.14.2	Impact on Biodiversity	45
1.7.14.3	Illicit and Uncontrolled Trade	45
1.7.14.4	Sustainable Sourcing Practices	45

1.7.14.5	Involving Communities and Benefits Sharing	45
1.8	Regulatory Scenario for Herbal Products in Modern Medicine	45
1.9	Approved Herbal Products	47
1.9.1	Herbal Medicines in the European Union	47
1.9.2	Herbal Medicines in the United States	47
1.9.3	Herbal Medicines in India	47
1.9.4	Herbal Products in Japan	47
1.9.5	US FDA-Approved Products	48
1.9.5.1	US FDA Approval Process for Herbal Products	48
1.9.5.2	Examples of US FDA-Approved Herbal Products	48
1.10	Conclusion	48
	References	49

2 Preparation of Extracts and Their Standardization 75

Neeraj K. Sethiya, Garima Agarwal, Samir Bhargava, Vijay S. Rana, Bhavna Kumar, Manmohan Singhal, Dheeraj Bisht, and Umesh K. Patil

Objectives 75

2.1	Introduction	75
2.2	Major Parameters	76
2.2.1	Solvents of Extraction	76
2.3	Minor Parameters	76
2.4	Important Terminology Used for the Preparation of Extracts and Standardization	76
2.5	Preparation of Extracts	77
2.6	Extraction of Plant Material	77
2.7	Extraction Methods	77
2.7.1	Solid-Liquid Extraction	77
2.7.1.1	Separation of Essential Oil	78
2.7.1.2	Preparation of Plant Extracts	80
2.7.2	Liquid-Liquid Extraction	82
2.8	Types of Extractions	82
2.9	Methods of Fractionation and Separation of Phytoconstituents	83
2.9.1	SCFET	83
2.9.2	CCCET	83
2.9.3	Preparative HPLC	83
2.9.4	Flash Chromatography	83
2.10	Factors Affecting Selection of Extraction Method	83
2.11	Standardization	83
2.12	Conclusion	85
	References	85

3 Isolation and Purification of Phytoconstituents 91

Shreya Sen Sarma, Biswajit Singh, Sushil K. Chaudhary, and Deepak Kumar

Objective 91

3.1	Introduction	91
3.2	Isolation and Purification	92
3.2.1	Non-chromatographic Separation Techniques	92
3.2.1.1	pH-Dependent Separation	92
3.2.1.2	Depending on Solvent Polarity	93
3.2.1.3	Distillation	94
3.2.1.4	Precipitation and Crystallization	94
3.2.1.5	Dialysis	95
3.2.1.6	Salt-Assisted Liquid-Liquid Extraction	95
3.2.1.7	Ultrafiltration	95

3.2.1.8	High-Performance Capillary Electrophoresis	95
3.2.1.9	Molecular Imprinting Technique	96
3.2.2	Chromatographic Separation Techniques	96
3.2.2.1	Liquid–Liquid Chromatographic Techniques	97
3.2.2.2	Solid–Liquid Chromatographic Techniques	98
3.3	Hyphenated Techniques and Metabolomics	104
3.4	Chemical Fingerprinting	107
3.5	Bio-Assay-Guided Isolation	107
3.6	Conclusion	108
	References	108
4	Natural Polysaccharides for Designing Herbal Formulations	119
	<i>Saumyadeep Bora, Shuchi Patel, Shreyansh Sharma, Deep Pooja, and Hitesh Kulhari</i>	
	Objectives	119
4.1	Introduction	119
4.2	Classification of Natural Polysaccharides	120
4.3	General Properties and Applications of Important Natural Polysaccharides	122
4.3.1	Chitosan	122
4.3.2	Alginates	122
4.3.3	Pectin	122
4.3.4	Dextran	122
4.3.5	Starch	125
4.3.6	Cellulose	125
4.3.7	Xanthan Gum	125
4.3.8	Gum Karaya	126
4.3.9	Gum Tragacanth	126
4.3.10	Agar	126
4.3.11	Gatti Gum	127
4.3.12	Gellan Gum	127
4.4	Conclusion and Future Perspectives	127
	Acknowledgments	128
	References	128
5	Principles of Sustained, Controlled, and Targeted Delivery of Herbal Actives	139
	<i>Aseem Setia, Abhishesh K. Mehata, Chandrashekar Singh, Paresh Badgujar, and Madaswamy S. Muthu</i>	
	Objectives	139
5.1	Introduction	139
5.2	Need for a Drug Delivery System	140
5.3	Solubility and Dissolution-Enhanced Drug Delivery Systems	140
5.4	Modified-Release Drug Delivery System	141
5.5	Types of Modified Drug Delivery Systems	141
5.5.1	Dissolution-Controlled Drug Delivery Systems	141
5.5.2	Diffusion-Controlled Drug Delivery Systems	146
5.5.3	Osmotic-Controlled Drug Delivery Systems	146
5.5.4	Erosion-Controlled Drug Delivery Systems	147
5.5.5	Ion Exchange Resins-Controlled Drug Delivery Systems	147
5.6	Plant Actives and Extracts as a NDDS	148
5.7	Drug Delivery Systems of Herbal Actives	150
5.7.1	Controlled-Release Formulations for Herbal Actives	150
5.7.2	Phytosomes of Herbal Actives	151
5.7.3	Liposomes of Herbal Actives	152
5.7.4	Transdermal Drug Delivery System for Herbal Actives	152

5.7.4.1	Microemulsions and Microspheres for Herbal Actives	152
5.7.4.2	Ethosomes for Herbal Actives	153
5.8	Targeted Drug Delivery Systems	154
5.9	Clinical Trials of Herbal Actives	155
5.10	Commercially Available Herbal Actives Drug Delivery System	156
5.11	Conclusion and Future Perspective	156
	References	157

6 Formulation and Delivery Issues for Active Ingredients of Herbal Medicines, Nutraceuticals, and Cosmetics: Comparisons to Small-Molecule Drugs 163

Monika Ola, Rajveer Bhaskar, Pradeep S. Patil, Sangita V. Badgujar, and Nitin G. Haswani

	Objectives	163
6.1	Introduction	163
6.2	Incompatibility Within Formulation	164
6.2.1	Types of Incompatibility	164
6.2.1.1	Physical Incompatibilities	167
6.2.1.2	Chemical Incompatibility	167
6.2.2	Incompatibility with Combination Therapy	167
6.3	Challenges Associated with Herbal Formulations	167
6.3.1	Difficulty in Assessing the Active Component from the Natural Product	168
6.3.2	Cultivation and Collection from Different Regions	168
6.3.3	Adulteration	168
6.3.4	Imperfect Preparation	168
6.3.5	Impact of Regulatory Policies on the Use of Natural Products	168
6.3.6	Challenges Associated with Quality Control of Product	168
6.3.7	Herbal Formulation and Heavy Metals	168
6.3.8	Challenges in Bioavailability of Herbal Actives	168
6.3.9	First-Pass Metabolism	168
6.3.10	Safety Concerns	169
6.3.11	Compositional Variation	169
6.4	Stability Issues	169
6.4.1	Environmental Factors	169
6.4.2	Storage Conditions	170
6.4.3	Moisture Content and Interaction with Packaging Material	170
6.4.4	Microbial Growth and Decomposition due to Molds and Fungi	170
6.4.5	Infestation by Insects	170
6.4.6	Drug Interactions	170
6.5	Solubility Issues	170
6.5.1	Formulation Stability and Effectiveness	171
6.5.2	Product Performance and User Experience	171
6.5.3	Consumer Expectations and Regulatory Considerations	171
6.5.4	Cosmetics or External Herbal Actives	171
6.5.4.1	Skin Penetration	171
6.5.4.2	Stability and Shelf Life	171
6.5.4.3	Formulation Flexibility	171
6.5.4.4	Formulation Integrity	171
6.5.4.5	Sensory Evaluation	171
6.5.4.6	Regulatory Compliance	171
6.5.5	Challenges and Solutions	171
6.6	Permeability Issues	172
6.6.1	Factors Affecting Permeability	172
6.7	Bioavailability and Pharmacokinetics	172

6.7.1	Bioavailability	172
6.7.2	Pharmacokinetics	172
6.7.2.1	Absorption of Natural Products in the Gastrointestinal Tract	173
6.7.2.2	Distribution of Natural Products in Body	173
6.7.2.3	Metabolism of Natural Products	173
6.7.2.4	Excretion of Natural Products	173
6.8	Factors Affecting Bioavailability of Natural Actives	173
6.8.1	Physicochemical Factors	174
6.8.2	Biological Factors	174
6.8.3	Pharmaceutical Factors	174
6.8.4	Patient-Related Factors	174
6.9	Factors Affecting the Pharmacokinetics of Herbal Formulation	174
6.9.1	Bioavailability of Active Compounds	174
6.9.2	Genetics	174
6.9.3	Age	174
6.9.4	Gender	175
6.9.5	Health Status	175
6.9.6	Herb–Drug Interactions	175
6.10	Modification of Herbal Actives Half-Life	175
6.10.1	Factors Affecting Half-Life of Herbal Actives	175
6.11	Strategies for Modifying the Half-Life of Herbal Actives	176
6.11.1	Formulation Approaches	176
6.11.2	Chemical Modifications	176
6.11.3	Biotechnological Approaches	176
6.11.4	Natural Enhancers	176
6.11.5	Challenges and Future Directions	176
6.12	Enhancement of Bioavailability of Herbal Actives	177
6.12.1	Strategies for Boosting the Bioavailability of Herbal Formulations	177
6.12.1.1	Nanoformulations	177
6.12.1.2	Phytochemical Alterations	177
6.12.1.3	Bioenhancers	178
6.12.1.4	Phytochemical Synergism	178
6.12.1.5	Biological Approaches	179
6.12.1.6	Co-Administration with Other Compounds	179
6.12.1.7	Implications and Future Perspectives for Bioavailability Enhancement Technique	180
6.13	Small Molecules (Synthetic Drugs) Versus Herbal Actives	180
6.14	Conclusion	182
	References	182

Section II Conventional Formulations 193

7	Stability of Herbal Formulations: Emerging Trends and Techniques	195
	<i>Dimple S. Lalchandani, Laltanpuii Chenkual, and Pawan K. Porwal</i>	
	Objectives	195
7.1	Introduction	195
7.2	Importance of Analytical Methods in the Stability Study of Herbal Formulations	196
7.3	Challenges Encountered in the Stability Study of Herbal Formulations	196
7.3.1	Presence of Heterogenous Complex Mixtures of Phytoconstituents	197
7.3.2	Variability in Herbal Sources	197
7.3.3	Contamination of Raw Material along with Adulteration and Substitution	197
7.3.4	Selection of Marker(s)	197

7.4	Analytical Techniques for Estimating the Stability of Herbal Formulations	197
7.4.1	High-Performance Liquid Chromatography	198
7.4.1.1	Method Development Parameters for Developing a Stability-Indicating Assay Method	198
7.4.1.2	Application of High-Performance Liquid Chromatography in Assessing Stability Parameters	198
7.4.2	High-Performance Thin-Layer Chromatography (HPTLC)	202
7.4.2.1	Method Development Parameters for Developing a Stability-Indicating Assay Method	202
7.4.2.2	Application of High-Performance Thin-Layer Chromatography in Assessing Stability Parameters	202
7.4.3	Gas Chromatography (GC)	205
7.4.3.1	Method Development Parameters for Developing a Stability-Indicating Assay Method	206
7.4.3.2	Application of Gas Chromatography in Assessing Stability Parameters	206
7.4.4	High-Performance Size-Exclusion Chromatography (HPSEC)	207
7.4.5	Other Analytical Techniques	207
7.5	Emerging Trends in Analytical Methods of Herbal Medicine	207
7.5.1	Liquid Chromatography-Mass Spectrometry-Based Fingerprinting	208
7.5.2	Gas Chromatography-Mass Spectrometry-Based Fingerprinting	209
7.5.3	Nuclear Magnetic Resonance (NMR) Spectroscopy	210
7.5.4	DNA Barcoding and Next-Generation Sequencing (NSG)	210
7.5.5	Chemometrics, Artificial Intelligence (AI), and Machine Learning (ML) Approaches	210
7.6	Quality Control and Assurance of Herbal Products	212
7.7	Challenges in Quality Assurance of Herbal Medicine	212
7.8	Regulatory Basis of Herbal Drug and Stability Testing	213
7.9	Conclusion	214
	References	214
8	Fast-Dissolving/-Disintegrating Herbal Dosage Forms	219
	<i>Debadri Banerjee, Vikas Anand Saharan, and Anupama Singh</i>	
	Objectives	219
8.1	Introduction	219
8.2	Principles of Disintegration	220
8.3	Natural and Synthetic Disintegrants	221
8.4	Orally Disintegrating Tablets (ODTs)	221
8.4.1	Herbal or Phytoconstituent-Based Orally Disintegrating Tablets ODTs	221
8.4.2	Excipients Used for the Preparation of Orally Disintegrating Tablets	227
8.4.3	Orally Disintegrating Tablets in Traditional Indian Medicine	227
8.4.4	Methods of Preparing Herbal Orally Disintegrating Tablets	227
8.5	Orally Disintegrating Films (ODFs)	229
8.5.1	Natural Film-Forming Polymers	230
8.5.2	Methods of Preparing Herbal Orally Disintegrating Films	230
8.6	Fast-Disintegrating Pellets	232
8.6.1	Methods of Preparing Pellets	232
8.7	Fast-Dissolving/-Disintegrating Dosage Forms of Phytoconstituents	233
8.8	Challenges	234
8.9	Clinical Trials	235
8.10	Marketed Formulation	236
8.11	Conclusion	236
	References	236
9	Herbal Formulations for Transmucosal Drug Delivery	243
	<i>Debadri Banerjee, Vikas Anand Saharan, and Anupama Singh</i>	
	Objectives	243
9.1	Introduction	243
9.2	Mucoadhesion	243
9.2.1	Mucoadhesion Theories	243

9.2.2	Various Stages of Mucoadhesion	244
9.2.3	Various Factors Affecting Mucoadhesion	245
9.2.3.1	Physicochemical Factors	245
9.2.3.2	Environmental Factors	246
9.2.3.3	Physiological Factors	246
9.3	Transcellular and Paracellular Permeation	246
9.4	Various Transmucosal Routes: Drug Delivery Aspects	247
9.4.1	Intranasal	248
9.4.2	Oromucosal	249
9.4.3	Rectal	253
9.4.4	Vaginal	255
9.5	Phytochemical Delivery Through Transmucosal Route	257
9.6	Challenges	258
9.7	Clinical Trials	261
9.8	Marketed Herbal Mucoadhesive Products	261
9.9	Conclusion	261
	References	264
10	Solid Dispersions	271
	<i>Kirti Shirsath, Indrani Maji, Srushti Mahajan, Mayur Aalhate, Ujala Gupta, and Pankaj K. Singh</i>	
	Objectives	271
	Abbreviations	271
10.1	Introduction	271
10.2	Components for Solid Dispersion-Based Formulations	273
10.2.1	Properties of Herbal Drugs	274
10.2.2	Properties of Excipients/Carriers	275
10.3	Physiological Principle Behind Drug Absorption	276
10.4	Methods of Preparation	277
10.4.1	Solvent Evaporation Technique and Spray Drying	277
10.4.2	Hot-Melt Extrusion (HME)	278
10.4.3	Freeze-Drying	279
10.4.4	Supercritical Fluid Method	280
10.4.5	Kneading Method	280
10.4.6	Fusion Method	280
10.5	Characterization of Solid Dispersion	281
10.6	Drug Delivery Applications	283
10.6.1	Pharmacokinetic Point of View	283
10.6.2	Pharmacodynamic Point of View	283
10.6.3	Therapeutic Point of View	285
10.7	Challenges in the Extraction of Phytoconstituent	286
10.8	Conclusion	287
	References	287
11	Formulating Pharma-, Nutra-, and Cosmeceutical Products from Herbal Substances	299
	<i>Pooja Khairnar, Tejaswini Kolipaka, Giriraj Pandey, Vivek Phatale, Aachal Hedao, and Saurabh Srivastava</i>	
	Objectives	299
11.1	Introduction	299
11.2	Challenges for the Delivery of Herbal Actives	300
11.3	Rationale for Pelletization	300
11.4	Ideal Characteristics and Advantages of Pelletization of Herbal Actives	301
11.4.1	Ideal Characteristics of the Pellets	301
11.4.2	Advantages of the Herbal Pellets and Pelletization	301
11.5	Phenomenon of Pelletization	302

11.5.1	Compaction	302
11.5.2	Layering	302
11.5.3	Agitation	302
11.5.4	Globulation	303
11.6	Pelletization Techniques	303
11.6.1	Extrusion–Spheronization	303
11.6.2	Hot-Melt Extrusion–Spheronization	304
11.6.3	Solvent-Free Cold Extrusion–Spheronization	304
11.6.4	Microsize and Nano-Extrusion	304
11.6.5	Powder/Suspension/Solution Layering	304
11.6.6	Hot-Melt Coating	305
11.6.7	Direct Pelletization	305
11.6.8	Hot-Melt Direct Pelletization	305
11.6.9	Pelletization in High-Shear Mixers	305
11.6.10	Jet-Cutting	305
11.6.11	Cryopelletization	305
11.6.12	Freeze Pelletization	305
11.7	Characterization of Pellets	306
11.7.1	Particle Size Distribution	306
11.7.1.1	Sieving	306
11.7.1.2	Microscopy	306
11.7.2	Particle shape	307
11.7.2.1	Sphericity	307
11.7.2.2	Aspect Ratio	307
11.7.3	Surface area	307
11.7.3.1	Adsorption Method	307
11.7.3.2	Air Permeability Method	307
11.7.4	Porosity	307
11.7.5	Density	307
11.7.6	Hardness and Friability	308
11.7.7	Flow properties	308
11.7.8	Disintegration	309
11.7.9	Dissolution	309
11.8	Delivery Aspects of Pellets for Herbal Actives	309
11.8.1	Delivery of Pharmaceuticals	309
11.8.1.1	Pellets as Controlled-Release Delivery Systems	309
11.8.1.2	Pellets as Site-Specific Delivery Systems	310
11.8.2	Delivery of Nutraceuticals	311
11.8.3	Novel Strategies for Pellet Designing	311
11.8.3.1	Multiple-Unit Pellet System	311
11.8.3.2	Self-Emulsifying Pellets	312
11.8.3.3	3D-Printed Pellets	313
11.9	Regulatory Considerations Toward Clinical Translation	314
11.10	Marketed Products	316
11.11	Conclusion and Future Perspective	316
	Acknowledgments	317
	Conflict of Interest	317
	References	317
12	Hydrogels as Delivery Systems in Herbal Medicine	323
	<i>Khushi Rode, Nandkishor Rajankar, Mayur Aalhat, Srushti Mahajan, Indrani Maji, Ujala Gupta, and Pankaj K. Singh</i>	
	Objectives	323
12.1	Introduction	323

12.2	Application of Hydrogels	324
12.2.1	Wound Dressing	325
12.2.2	Drug Delivery	325
12.2.3	Tissue Engineering	325
12.2.4	Contact Lens	325
12.2.5	Gene Delivery	325
12.3	Benefits of Hydrogels in Delivering Herbal Medicine	326
12.4	Hydrogels as an Effective Delivery of Nanocarrier System	330
12.4.1	Macroscopic Hydrogels with Natural Polymers	330
12.4.2	<i>In situ</i> Gelling Hydrogels	332
12.4.3	Shear-Thinning Hydrogels	334
12.4.4	Macroporous Hydrogels	334
12.4.5	Microgels and Nanogels	335
12.5	Modification in Hydrogel Properties to Effectively Deliver Herbal Medicine	335
12.6	Formulation of Hydrogels to Precisely Deliver Herbal Medicine	342
12.6.1	Strategies to be Employed While Formulating Hydrogels	342
12.6.2	Methods Utilized in the Formulation of Hydrogels	342
12.7	Challenges Associated with the Delivery of Hydrogels	343
12.8	Conclusion and Future Prospects	344
	References	346
13	Emulsions and Self-Emulsifying Delivery Systems for Herbal Actives	355
	<i>Puja Tripathy, Raju Barman, Rinku Baishya, and Deepak Kumar</i>	
	Abbreviations	355
	Objectives	355
13.1	Introduction	355
13.2	Emulsions	356
13.2.1	Micro-Emulsions (MEs)	357
13.2.2	Nanoemulsion (NEs)	357
13.2.3	Self-Emulsifying Delivery System (SEDDS)	357
13.3	Composition of Emulsion	357
13.3.1	Herbal Actives	357
13.3.2	Lipophilic Phase (Oils)	357
13.3.3	Surfactants	358
13.3.4	Co-Surfactant	358
13.4	Thermodynamics of EMs	358
13.5	Preparation Methods	359
13.5.1	High Energy Methods	359
13.5.1.1	Ultrasonication Homogenization	359
13.5.1.2	Rotor/Stator Homogenization	359
13.5.1.3	High-Pressure Homogenizations	360
13.5.2	Low-Energy Methods	361
13.5.2.1	Spontaneous Emulsification Method (SEM)	361
13.5.2.2	Phase Inversion Method (PIM)	361
13.6	Characterization of Emulsions	362
13.6.1	Nuclear Magnetic Resonance (NMR)	362
13.7	Optimization of Emulsions	363
13.7.1	Pseudo-Ternary Phase Diagram (PTPD)	363
13.7.2	Statistical Modelling	364
13.8	Herbal-Active Loaded Emulsions	364
13.9	Clinical Studies	364
13.10	Conclusion and Future Perspectives	371
	References	371

Section III Advanced Formulations 379

14	Chronotherapeutic Delivery Systems 381
	<i>Akanksha Chaturvedi, Priyanka Arora, and Rahul Shukla</i>
	Objectives 381
14.1	Introduction 381
14.2	Principles of Biological Clock 382
14.3	Need for a Chronotherapeutic Drug Delivery System 383
14.3.1	Biological Tolerance 383
14.3.2	Chronotherapeutic Conditions 383
14.3.3	First-Pass Metabolism 383
14.3.4	Chronic Treatment 383
14.3.5	Tolerance 383
14.3.6	Local Therapeutic Need 383
14.3.7	Gastric Irritation 383
14.4	Mechanisms of Chronotherapeutic Drug Delivery Systems 384
14.5	Development of Chronotherapeutic Delivery Systems 384
14.5.1	Time-Controlled Chronotropic Systems 384
14.5.2	Single-Unit Capsule-Based Systems 384
14.5.2.1	Capsular Systems Operating via Osmosis 384
14.5.2.2	Pulsatile Systems with Erodible Soluble Barrier Coatings 384
14.5.2.3	Pulsatile System Rupturable Coating 384
14.5.3	Multiparticulate/Multiple-Unit System 384
14.5.3.1	Pulsatile System Rupturable Coating 385
14.5.3.2	Osmotic-Based Rupturable Coating System 385
14.5.3.3	Pulsatile Delivery Achieved by Modulation of Membrane Permeability 385
14.5.4	Stimuli-Induced Pulsatile Drug Delivery Systems 385
14.5.4.1	pH-Sensitive Drug Delivery System 385
14.5.4.2	Chemical Stimuli-Induced Pulsatile Release 385
14.5.4.3	Glucose-Responsive Insulin Release Devices 385
14.5.4.4	Pulsatile Release Triggered by Inflammation 385
14.5.5	Externally Regulated Pulsatile Drug Delivery 386
14.5.5.1	Electroresponsive Pulsatile Release Systems 386
14.5.5.2	Sonicated Ultrasound 386
14.5.5.3	Pulsatile Release Caused by Magnetic Fields 386
14.6	Technological Advancement in Chronotherapeutic Drug Delivery Systems 386
14.6.1	Chronomodulated Systems for Oral Route 386
14.6.1.1	CODAS Technology 386
14.6.1.2	CEFORM Technology 387
14.6.1.3	OROS Technology 387
14.6.1.4	DIFFUCAPS Technology 387
14.6.1.5	EGALET Technology 387
14.6.1.6	GEOCLOCK Technology 387
14.6.1.7	TIMERx Technology 388
14.6.2	Chronomodulated Systems for Transdermal Route 388
14.6.2.1	Crystal Reservoir System 388
14.6.3	Chronomodulated Delivery Systems by Implant Route 388
14.6.3.1	Chronomodulated Infusion Pumps 388
14.6.3.2	Microfabrication 388
14.7	Phytomedicine-Loaded Chronotherapeutic Drug Delivery Systems in Therapeutic Intervention 388
14.8	Chinese Herbal Medicines-Incorporated Chronotherapeutic Drug Delivery Systems 391
14.9	Herbal Excipients Modulating Chronotherapeutic Drug Delivery Systems 391

14.10	Clinical Translation and Patented Chronotherapeutic Drug Delivery Systems-Based Formulations	392
14.11	Challenges/Hurdles in Chonopharmaceutical Drug Research and Development	393
14.11.1	Rhythmic Biomaterials and System Design Hurdles	393
14.11.2	Rhythm Engineering and Modeling Hurdles	393
14.11.3	Regulatory Hurdles	394
14.12	Conclusion and Future Perspectives	395
	References	395
15	Liposomes-Based Delivery of Phytoconstituents	399
	<i>Shuchi Patel, Mahima Jadav, Deepali Sammal, Hitesh Kulhari, and Deep Pooja</i>	
	Objectives	399
15.1	Introduction	399
15.2	Types of Liposomes	399
15.2.1	Liposome Classification According to Their Structural Characteristics	399
15.2.2	Liposomes Classified Based on Their Preparation Method	400
15.2.3	Liposomes Classified Based on Their Composition	401
15.2.4	Classification of Liposomes Based on Their Stimuli-Response	401
15.3	Preparation of Liposomes by Different Methods	401
15.3.1	Film Hydration	402
15.3.2	Reverse-Phase Evaporation	402
15.3.3	Solvent Injection	402
15.3.4	Detergent Removal Technique	403
15.3.5	Heating Method	403
15.3.6	Microfluidic Channel Method	403
15.3.7	Supercritical Fluid Method	403
15.4	Delivery of Phytoconstituents Using Liposomes	403
15.4.1	Anticancer Liposome Systems	403
15.4.1.1	Prostate Cancer	404
15.4.1.2	Breast Cancer	405
15.4.1.3	Lung Cancer	405
15.4.1.4	Leukemia Cancer	405
15.4.1.5	Colorectal Cancer	405
15.4.2	Delivery of Antioxidant Phytoconstituents	408
15.4.3	Delivery of Anti-inflammatory Phytoconstituents	408
15.4.4	Delivery of Antimicrobial Phytoconstituents	409
15.4.5	Delivery of Hepatoprotective Phytoconstituents	409
15.4.6	Delivery of Neuroprotective Phytoconstituents	412
15.4.7	Delivery of Phytoconstituents with Other/Miscellaneous Activities	412
15.5	Conclusion	412
	Acknowledgments	412
	References	413
16	Nanoparticles-Mediated Delivery of Herbal Actives	419
	<i>Priyanka Dubey, Shivangi Bharadwaj, Shruti Richa, Kajal Kumari, Payal Khesarwani, and Swapnil Sharma</i>	
	Objectives	419
16.1	Introduction	419
16.2	General Principles of Nanoparticle-Mediated Herbal Actives	420
16.3	Types of Herbal Nanoformulations	422
16.3.1	Lipid-Based Nanocarriers	422
16.3.1.1	Solid Lipid Nanoparticles (SLNs)	422
16.3.1.2	Liposomes	422
16.3.1.3	Nanoemulsion	425

16.3.1.4	Phytosomes	425
16.3.2	Polymeric-Based Nanocarriers	425
16.3.2.1	Dendrimers	426
16.3.2.2	Polymeric Micelles	426
16.3.2.3	Nanospheres and Nanocapsules	428
16.3.2.4	Polymer Drug Conjugates	428
16.3.3	Inorganic Nanocarriers	428
16.3.3.1	Gold Nanoparticles (AuNPs)	428
16.3.3.2	Silver Nanoparticles (AgNPs)	428
16.3.3.3	Iron Oxide Nanoparticles	431
16.3.3.4	Mesoporous Silica Nanoparticles (MSNs)	431
16.3.3.5	Carbon Nanotubes (CNTs)	431
16.3.4	Other Nanocarriers	432
16.3.4.1	Quantum Dots	432
16.4	Methods of Preparation for Herbal Active Nanoformulations	432
16.4.1	Bottom-Up Approach	432
16.4.1.1	Co-Precipitation	432
16.4.1.2	Nanoprecipitation	432
16.4.1.3	Solvent Evaporation	433
16.4.2	Top-Down Approach	434
16.4.2.1	High-Pressure Homogenization (HPH)	434
16.4.2.2	Electrospinning	435
16.4.2.3	Mechanical Milling	435
16.4.2.4	Ultra Sonication	435
16.4.2.5	Laser Ablation	435
16.5	NPs Mediated Delivery of Herbal Actives to Treat Different Diseases	435
16.5.1	Delivery Approaches for Cancer Treatment	436
16.5.2	Delivery Approaches for Microbial Infection	436
16.5.3	Delivery Approaches for Cardiovascular Disease (CVD)	437
16.5.4	Delivery Approaches for Metabolic Syndrome	437
16.5.5	Delivery Approaches for Neurodegenerative Disorder	438
16.6	New Approaches, Challenges, and Limitations of Herbal-Mediated Nanoformulation	439
16.7	Clinical Trials and US Food and Drug Administration-Approved Herbal Active Nanoformulations	442
16.8	Conclusion and Future Prospective	442
	References	442

17 Herbal Extracts and Phytoconstituents-Loaded Transferosomes, Ethosomes, and Transdermal Patches in Drug Delivery 453

Nirmal Morya, Keshav Hirave, Debadri Banerjee, Anupama Singh, and Vikas Anand Saharan

Objectives 453

17.1	Introduction	453
17.2	Delivery Aspects	454
17.2.1	Intranasal Delivery	454
17.2.2	Transdermal Delivery	455
17.3	Transferosomes	456
17.3.1	Principle	456
17.3.2	Advantages of Transferosomes	456
17.3.3	Structure and Composition	457
17.3.4	Methods of Preparation	457
17.3.4.1	Thin-Film Hydration Technique/Rotary Evaporation–Sonication Method	458
17.3.4.2	Reverse-Phase Evaporation Method	458
17.3.4.3	Vortexing–Sonication Method	458

17.3.4.4	Ethanol Injection Method	458
17.3.4.5	Modified Handshaking Process	459
17.3.4.6	Suspension Homogenization Method	459
17.3.4.7	Sonication–Centrifugation Process	459
17.3.4.8	High-Pressure Homogenization Technique	459
17.3.4.9	Aqueous Lipid Suspension Process	459
17.3.5	Formulations of Transferosomes	459
17.3.5.1	Plant Extract-Loaded Transferosome Formulation	459
17.3.5.2	Phytoconstituents-Loaded Transferosome Formulation	461
17.4	Ethosomes	466
17.4.1	Principle	467
17.4.2	Advantages	467
17.4.3	Composition	467
17.4.4	Methods of Preparation	467
17.4.4.1	Cold Method	467
17.4.4.2	Hot Method	468
17.4.4.3	Mechanical Dispersion	468
17.4.4.4	Thin-Film Hydration	468
17.4.4.5	Ethanol Injection Method	468
17.4.5	Formulations of Ethosomes	468
17.4.5.1	Plant Extract-Loaded Ethosome Formulation	468
17.4.5.2	Phytoconstituents-Loaded Ethosome Formulation	471
17.4.6	Marketed Formulations	476
17.5	Transdermal Patches	476
17.5.1	Principle	476
17.5.2	Advantages	476
17.5.3	Composition of Transdermal Patch	477
17.5.4	Method of Preparation of Single-Layered Patches	477
17.5.4.1	Solvent Casting Method	477
17.5.4.2	Electrospinning	478
17.5.4.3	Solvent Evaporation Method	478
17.5.5	Formulations of Transdermal Patch	478
17.5.5.1	Plant Extract-Loaded Transdermal Patch Formulations	478
17.5.5.2	Phytoconstituent-Loaded Transdermal Patch Formulations	481
17.5.6	Marketed Formulations	483
17.5.7	Clinical Trials	486
17.6	Challenges in Herbal Active Delivery	486
17.7	Conclusion	486
	References	487
18	Dendrimers as Nanocarriers for Phytoceuticals	495
	<i>Surojit Banerjee, Keshav Hirave, Deep Pooja, Hitesh Kulhari, Anupama Singh, and Vikas Anand Saharan</i>	
	Objectives	495
18.1	Introduction	495
18.2	Principles of Dendrimers	496
18.2.1	Physicochemical Principles	496
18.2.1.1	Size	496
18.2.1.2	Shape	497
18.2.1.3	Surface Groups	497
18.2.1.4	Surface Charge	497
18.2.1.5	Monodispersity	497
18.2.1.6	Molecular Weight	497

18.2.1.7	Internal Architecture	497
18.2.1.8	Encapsulation Efficiency	497
18.2.1.9	Solubility	497
18.2.1.10	Stability	498
18.2.2	Biological Principles	498
18.2.2.1	Cellular Uptake	498
18.2.2.2	Biocompatibility and Toxicity	498
18.2.2.3	Biodistribution and Clearance	498
18.2.2.4	Interaction with Biomolecules	498
18.2.3	Physiological Principles	499
18.2.3.1	Blood Circulation and Immune Response	499
18.2.3.2	Renal and Hepatic Clearance	499
18.2.3.3	Tumor Targeting and Enhanced Permeability and Retention Effect	499
18.3	Types of Dendrimers	499
18.3.1	Polyether Dendrimers	500
18.3.2	Polyester Dendrimers	500
18.3.3	Core–Shell/Tecto Dendrimers	500
18.3.4	Triazine Dendrimers	500
18.3.5	Citric Acid Dendrimers	501
18.3.6	Phosphate Dendrimers	501
18.3.7	Melamine Dendrimers	501
18.3.8	Polyether Imine Dendrimers	501
18.3.9	Polyether–Polyester Dendrimers	502
18.3.10	PAMAM Dendrimers	502
18.3.11	PPI Dendrimers	502
18.3.12	Glycodendrimers	502
18.3.13	Chiral Dendrimers	502
18.3.14	PLL Dendrimers	503
18.3.15	Hybrid Dendrimers	503
18.3.16	PAMAM–Organosilicon Dendrimers	503
18.3.17	Liquid Crystalline Dendrimers	503
18.3.18	Polyurea Dendrimers	503
18.3.19	Peptide Dendrimers	504
18.3.20	Janus Dendrimers	504
18.4	Dendrimer Formulations	504
18.4.1	Effect of Dendrimer Core, Dendrimer Branches (Arms), and Surface Functional Groups	505
18.4.2	Phytoconstituents; the Active Ingredients	505
18.4.3	Enhancing Drug Solubility via Dendrimer Formulation Modification with Solubilizers	506
18.4.4	Cross-Linkers for Altering Stability and Functionality	506
18.4.5	Solvent System	507
18.5	Preparation Process	508
18.5.1	Preparation Methods for Phytoconstituent–Dendrimer Conjugates	508
18.5.1.1	Direct Addition Method	508
18.5.1.2	Solvent Evaporation Method	508
18.5.1.3	Dialysis Method	509
18.5.1.4	Sol–Gel Method	509
18.5.1.5	Cross-Linking Method	510
18.5.1.6	Nanoprecipitation Method	510
18.5.1.7	Coacervation Method	510
18.6	Toxicity of Dendrimers	511
18.6.1	Low-Generation Dendrimers (G0–G2)	511
18.6.2	Mid-Generation Dendrimers (G3–G4)	511

18.6.3	High-Generation Dendrimers (G5 and Above)	512
18.6.4	Strategies for Overcoming Dendrimer Toxicity	512
18.6.4.1	PEGylation	513
18.6.4.2	Folate Conjugation	513
18.6.4.3	Amino Acids/Peptide Conjugation	513
18.7	Challenges for Herbal Actives	514
18.7.1	Low Water Solubility	514
18.7.2	Poor Bioavailability	514
18.7.3	Rapid Degradation and Short Half-Life	515
18.7.4	Poor Permeability	515
18.7.5	Nontargeted Drug Delivery	515
18.7.6	Variability in Pharmacokinetics	516
18.7.7	Toxicity and Side Effects	516
18.8	Examples of Dendrimer-Based Delivery of Phytoconstituents	517
18.9	Preclinical Studies	517
18.10	Conclusion	523
	References	526
19	Applications of Carbon-Based Nanomaterials for the Delivery of Herbal Molecules	533
	<i>Saumyadeep Bora, Deep Pooja, Brahmaji R. Mutyala, and Hitesh Kulhari</i>	
	Objectives	533
19.1	Introduction	533
19.2	Properties of Herbal Molecules	534
19.2.1	Antioxidant Properties	535
19.2.2	Anti-Inflammatory Effects	535
19.2.3	Antimicrobial Activity	535
19.2.4	Cardioprotective Potential	535
19.2.5	Neuroprotective Effects	535
19.2.6	Metabolic Regulation	535
19.2.7	Anticancer Properties	535
19.3	Challenges Associated with the Delivery of Herbal Molecules	535
19.3.1	Poor Bioavailability and Pharmacokinetics	535
19.3.2	Safety and Toxicity Concerns	536
19.3.3	Lack of Standardization	536
19.3.4	Limited Scientific Validation	536
19.4	Role of Nanocarriers in Herbal Molecule Delivery	536
19.4.1	Enhanced Bioavailability	536
19.4.2	Enhanced Stability	536
19.4.3	Targeted Delivery and Reduced Side Effects	536
19.4.4	Controlled Drug Release	536
19.4.5	Combination Therapy	537
19.4.6	Overcoming BBB	537
19.5	Characteristics of Carbon-Based Nanomaterials for Herbal Molecule Delivery	537
19.6	Classification of Carbon-Based Nanomaterials	537
19.6.1	Carbon Nanotubes (CNTs)	538
19.6.2	Graphene, Graphene Oxide (GO), and Reduced Graphene Oxide (rGO)	538
19.6.3	Graphene or Carbon Quantum Dots (G/CQDs)	539
19.6.4	Fullerenes	539
19.6.5	Nanodiamonds (NDs)	539
19.7	Applications of Carbon-Based Nanomaterials in Herbal Molecule Delivery	539
19.7.1	Anticancer Application	539
19.7.2	Neurodegenerative Diseases	540
19.7.3	Antimicrobial Application	541

19.8	Conclusion and Future Perspectives	542
	Acknowledgments	542
	References	542
20	Phytoconstituents and Plant Extract-Based Formulations for Wound Healing	549
	<i>Keshav Hirave, Nirmal Morya, Surojit Banerjee, Anupama Singh, and Vikas Anand Saharan</i>	
	Objectives	549
20.1	Introduction	549
20.2	Mechanism of Wound Healing	550
20.2.1	Homeostasis	550
20.2.2	Inflammation Phase	551
20.2.3	Proliferation and Tissue Formation	553
20.2.4	Remodeling or Maturation Phase	553
20.2.4.1	Mechanism of Angiogenesis	553
20.3	Wound Classification	553
20.3.1	Acute Wounds	553
20.3.2	Closed Wounds	554
20.3.3	Open Wound	554
20.3.4	Incised Wounds	554
20.3.5	Laceration Wound	554
20.3.6	Puncture Wounds	554
20.3.7	Abrasive or Superficial Wounds	554
20.3.8	Penetration Wounds	554
20.3.9	Gunshot Wounds	554
20.3.10	Chronic Wounds	554
20.4	Factors Affecting Wound Healing	554
20.4.1	Local Factors	554
20.4.1.1	Infection	554
20.4.1.2	Oxygenation	554
20.4.1.3	Hypoxia	555
20.4.1.4	Edema	555
20.4.2	Systemic Factors	555
20.4.2.1	Age	555
20.4.2.2	Gender	555
20.4.2.3	Medication	555
20.4.2.4	Nutrition	555
20.4.2.5	Smoking	555
20.4.2.6	Alcoholism	555
20.4.2.7	Obesity	555
20.4.2.8	Stress	555
20.5	Nanocarrier in Wound Dressing	556
20.6	Medicinal Plants in Wound Healing/Plant Extracts, Extract Fractions and Phytoconstituent and Plant Extract Used in Wound Healing	556
20.6.1	Phytoconstituents and Plant Extracts in Wound Healing	557
20.6.1.1	Phenolics and Polyphenolics	558
20.6.1.2	Terpenoids	561
20.6.1.3	Alkaloids	563
20.6.1.4	Steroids	564
20.6.1.5	Quinones	564
20.7	Plant-Derived Phytoconstituent and Extract-Based Formulation for Wound Healing	567
20.8	Clinical Trials	573
20.9	Role of Different Plants in Wound Healing	573
20.9.1	<i>Tridax procumbens</i>	573

20.9.2	<i>Centella asiatica</i>	579
20.9.3	<i>Calendula officinalis</i>	579
20.9.4	<i>Althaea officinalis</i>	580
20.9.5	<i>Rosmarinus officinalis/Salvia rosmarinus</i>	580
20.9.6	<i>Melaleuca alternifolia</i>	581
20.9.7	<i>Salvia officinalis</i>	581
20.9.8	<i>Achillea millefolium</i>	581
20.9.9	<i>Acalypha indica</i>	582
20.9.10	<i>Tectona grandis</i> (teak)	582
20.9.11	<i>Embelia ribes</i>	583
20.9.12	<i>Astragalus membranaceus</i>	583
20.9.13	<i>Aloe vera</i>	583
20.9.14	<i>Rheum officinale</i>	584
20.9.15	<i>Rheum palmatum</i>	584
20.10	Marketed Formulations/Commercial Products	584
20.11	Some Patented Innovations in Wound Healing	585
20.12	Future Directions and Challenges	585
20.13	Conclusion	589
	References	589
21	Chemo-Herbal Combination Drug Delivery for Cancer Management	599
	<i>Shivangi Bharadwaj, Priyanka Dubey, Shruti Richa, Kajal Kumari, Payal Kesarwani, Kanika Verma, and Swapnil Sharma</i>	
	Objectives	599
21.1	Introduction	599
21.2	Challenges in Targeting Chemo-Herbal Drugs: Overcoming Physicochemical, Biological, and Physiological Barriers for Effective Drug Delivery	601
21.3	Optimizing Drug Delivery Strategies for Chemo-herbal Drugs: Overcoming Barriers and Enhancing Therapeutic Efficacy with Effective Targeting	602
21.3.1	Lipid-based Nanoparticle	602
21.3.1.1	Liposomes	602
21.3.1.2	Nanoemulsion	603
21.3.1.3	Solid Lipid Nanoparticles	603
21.3.1.4	Niosomes	603
21.3.2	Polymer-based Nanomaterials	604
21.3.2.1	Nanogel	604
21.3.2.2	Nanomicelles	604
21.3.2.3	Nanocapsule	605
21.3.2.4	Nanofibers	605
21.4	Delivery Aspects of Chemo-Herbal Formulation in Cancer Therapy	614
21.4.1	Encapsulated Combinatorial Approach for Herbal and Chemotherapeutic Medications	614
21.4.2	Encapsulated Combinatorial Approach for Herbal and Hormone Medications	617
21.4.3	A Combinatorial Approach Encapsulating Herbal and Gene Treatment	617
21.4.4	Encapsulated Combinatorial Approach to Herbal and Immunomodulatory Medicines	620
21.5	Clinical Trials of Chemo-Herbal Formulations	621
21.6	Conclusion and Future Perspective	624
	Abbreviations	624
	References	625
22	Protein Nanocarriers for the Delivery of Phytoconstituents	633
	<i>Ngangom Bidyarani, Kulandaivelu Velmourougane, Umesh Kumar, and Radha Prasanna</i>	
	Objectives	633
22.1	Introduction	633

22.2	Protein Nanocarriers	633
22.2.1	Types of Protein-Based Nanocarriers	634
22.3	Methods of Preparation of Protein-Based Nanocarriers	634
22.4	Protein Nanocarriers for Phytoconstituents Delivery	635
22.5	Prospects of Nanotechnology for Delivery Purposes	637
22.6	Current Scenario and the Path Ahead	638
22.7	Conclusions	638
	References	639

Section IV Regulatory Challenges 643

23	Nonclinical Characterization and Documentation for Marketing Authorizations of Herbal Formulations	645
	<i>Swati Dobhal, Nitish S. Jangwan, Shradha Bisht, Vikas Anand Saharan, and Mamta F. Singh</i>	
	Objectives	645
23.1	Introduction	645
23.2	Nonclinical Characterization of Herbal Formulations: Pharmacodynamics, Toxicology and Pharmacokinetic Studies	646
23.2.1	Overview of Good Laboratory Practices and Its Implementation in Nonclinical Studies	646
23.2.2	Nonclinical Efficacy and Safety Assessment	647
23.2.2.1	General Pharmacology/Pharmacodynamic Studies	647
23.2.2.2	Nonclinical Toxicological Studies	647
23.2.2.3	Safety Pharmacology Studies	650
23.2.2.4	Nonclinical Pharmacokinetic and Toxicokinetic Studies	651
23.3	Regulatory Approvals for Marketing Herbal Formulations: A Global Overview of Documentation Requirements	652
23.3.1	US FDA and Dietary Supplement Health and Education Act: Documentation Requirements for Marketing Authorization in the United States	652
23.3.1.1	Regulations for Dietary Supplements	652
23.3.1.2	Herbal Medicines and Formulations	654
23.3.1.3	Botanical Drugs	654
23.3.2	European Medicines Agency and Documentation Requirements for Marketing Authorization in the European Union	654
23.3.3	Medicines and Healthcare Products Regulatory Agency and Documentation Requirements for Marketing Authorization in the United Kingdom	655
23.3.4	Food and Drug Administration of China and Documentation Requirement for Marketing Authorization in China	658
23.3.5	Ministry of Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy and Central Drugs Standard Control Organization in India and Documentation Requirements for Marketing Authorization of Herbal Products in India	659
23.3.6	Ministry of Health and Welfare and Documentation Requirements for Marketing Approval in Japan	661
23.3.7	Medicines Control Council and Documentation Requirements for Marketing Approval in South Africa	663
23.3.8	Canadian Health Protection Branch and Documentation Requirements for Marketing Approval in Canada	663
23.3.9	German Medicine Act and Documentation Requirements for Marketing Approval in Germany	667
23.3.10	Regulatory Agencies and Documentation Requirements for Marketing Approval in Russia	667
23.3.11	Regulatory Agencies and Documentation Requirements for Marketing Approval in Association of South East Asian Nations	668
23.4	Challenges	668
23.4.1	Authenticity and Quality Control	668
23.4.2	Pharmacological and Toxicological Challenges	669
23.4.3	Safety Monitoring and Pharmacovigilance	669

23.4.4	Regulatory Compliance	669
23.5	Conclusion	669
	References	669

24 Quality Challenge in Regulatory Approval of Medicinal Products Containing Combinations of Herbal Substances 677

Siddheshwar Kisan Chauthe, Soham Rajyaguru, Aditi Puranik, Nishi Yadao, and Kajal Rathod

	Objectives	677
24.1	Introduction to Phytomedicines	677
24.2	Classification of Herbal Medicines Based on Regulatory Frameworks and Standards	678
24.3	Quality Challenges Related to Herbal Medicines	679
24.3.1	Identification and Authentication	679
24.3.2	Complexity in Chemical Constituents	680
24.3.3	Interactions in Polyherbal Formulations	680
24.3.4	Stability	681
24.3.5	Safety and Efficacy	683
24.3.6	Clinical Trials	683
24.4	Global Regulatory Landscape of Herbal Medicines	684
24.4.1	Indian Regulatory Guidelines	685
24.4.1.1	AYUSH	685
24.4.2	EMA Regulatory Guidelines	686
24.4.2.1	Guidelines Associated with Quality of Herbal Substances/Products	686
24.4.2.2	Nonclinical Guidelines	688
24.4.2.3	Clinical Guidelines	688
24.4.2.4	Marketing Guidelines	688
24.4.3	US-FDA Botanical Guidance	689
24.4.3.1	Over-the-Counter (OTC) Drug Monograph	689
24.4.3.2	Drug Approval Under New Drug Application (NDA)	690
24.4.4	Canada and Rest of the World	690
24.5	WHO Regulatory Guidelines on GMP, GACP and Quality Control of Herbal Medicines	690
24.5.1	Good Manufacturing Practices (GMP)	690
24.5.2	Good Agricultural and Collection Practices (GACP)	691
24.5.2.1	Good Agricultural Practices for Medicinal Plants	691
24.5.2.2	Good Collection Practices for Medicinal Plants	692
24.5.3	Quality Control of Herbal Medicines	692
24.5.3.1	Physical Method	693
24.5.3.2	Analytical Method	694
24.6	Development and Standardization of Herbal Medicines	695
24.7	Challenges in the Development of Herbal Medicines	696
24.8	Conclusion	697
	References	698

25 Evidence-Based Clinical Assessment of Herbal Formulations: Traditional and Modern Insights 703

Debadri Banerjee, Surojit Banerjee, Pooja Shah, Anupama Singh, and Vikas Anand Saharan

	Objectives	703
25.1	Introduction	703
25.2	Indian Traditional Medicine	704
25.2.1	Case Studies of Clinical Assessment of Indian Traditional Medicines	704
25.2.2	Safety and Efficacy Concerns	705
25.3	Modern Herbal Medicine	706
25.3.1	Case Studies of Clinical Assessment of Modern Herbal Medicines	706

25.4	Regulatory Guidelines	708
25.4.1	World Health Organization (WHO) Guidelines and Resources on Clinical Trials	708
25.4.2	EMA (European Medicines Agency) Guidelines and Resources on Clinical Trials	710
25.4.3	FDA (Food and Drug Administration) Guidelines and Resources on Clinical Trials	710
25.4.4	Indian Guidelines and Resources on Clinical Trials	710
25.5	Validation Approaches and Clinical Assessments	713
25.5.1	Phytochemical Analysis	713
25.5.2	Toxicological Studies	714
25.5.3	Pharmacological Studies	714
25.5.4	Standardization Perceptions of Herbal Medicines	715
25.5.5	Clinical Assessments	716
25.5.6	Integrating Traditional Knowledge and Modern Science	716
25.6	Obstacles to Clinical Assessment of Herbal Formulations	716
25.6.1	Standardization Challenges	716
25.6.1.1	Botanical Identification	717
25.6.1.2	Growth and Cultivation Conditions	717
25.6.1.3	Time of Harvest	717
25.6.1.4	Postharvest Processing	717
25.6.1.5	Defining Active Ingredients	717
25.6.1.6	Quality Control	717
25.6.2	Complexity of Herbal Formulations	717
25.6.2.1	Multiple Active Constituents	717
25.6.2.2	Synergistic Effects	718
25.6.2.3	Unknown Mechanisms of Action	718
25.6.2.4	Metabolites and Biotransformation	718
25.6.3	Challenges in Preclinical Data Generation	718
25.6.3.1	Inadequate Animal Models	718
25.6.3.2	Limited Toxicological Data	718
25.6.3.3	Herb–Drug Interactions	718
25.6.4	Inadequate Clinical Trial Design	719
25.6.4.1	Placebo Control Challenges	719
25.6.4.2	Blinding Issues	719
25.6.4.3	Dose and Duration	719
25.6.4.4	Appropriate Endpoint	719
25.6.5	Regulation and Ethical Clearance	719
25.6.5.1	Lack of Harmonized Regulations	719
25.6.5.2	Difficulty in Securing Intellectual Property	719
25.6.5.3	Quality Control Issues	720
25.6.6	Ethical Considerations	720
25.6.6.1	Cultural Sensitivity	720
25.6.6.2	Benefit Sharing	720
25.6.6.3	Informed Consent	720
25.6.7	Economic and Funding Constrictions	720
25.6.7.1	Lack of Financial Incentives	720
25.6.7.2	Underfunding of Herbal Research	720
25.6.8	Lack of Public and Professional Acceptance	720
25.6.8.1	Health Care Provider Skepticism	721
25.6.8.2	Public Perception and Abuse	721
25.6.9	Clinical Issues	721
25.6.9.1	Pharmacovigilance	721
25.6.10	Factors Influencing Herbal Chemical Profiles	721
25.6.10.1	Geographical Origin	721